Diabetes drug found to improve cardiovascular outcomes across a range of heart and kidney conditions
A new meta-analysis shows sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular events in patients with either diabetes at high risk of atherosclerotic cardiovascular disease (ASCVD), ...
Apr 8, 2024
0
1